Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(8); doi: 10.25236/FMSR.2023.050818.

Rethinking on the pathogenesis, diagnosis and treatment of microvascular angina disease based on Chinese and foreign guidelines


Yichen Quan1, Yuanlin Lei2

Corresponding Author:
Yuanlin Lei

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

2Department of Cardiovascular Medicine, Xi'an Traditional Chinese Medicine Hospital, Xi'an, Shaanxi, 710021, China


Microvascular angina is a common non obstructive coronary artery ischemic heart disease in clinical practice. Its diagnosis is often empirical and can be mistaken for symptoms caused by non-cardiac factors, leading to delayed progression. With the development and upgrading of modern diagnostic and treatment technologies, the pathogenesis, diagnosis and treatment of MVA are receiving increasing attention from clinical physicians. More and more studies have confirmed that coronary microcirculation plays an important role in myocardial ischemia. This article summarizes the pathogenesis and diagnosis and treatment recommendations of microvascular angina in relevant Chinese and foreign guidelines, hoping to provide new diagnosis and treatment ideas for microvascular angina.


Microvascular angina; Coronary microvascular disease; Review

Cite This Paper

Yichen Quan, Yuanlin Lei. Rethinking on the pathogenesis, diagnosis and treatment of microvascular angina disease based on Chinese and foreign guidelines. Frontiers in Medical Science Research (2023) Vol. 5, Issue 8: 130-135. https://doi.org/10.25236/FMSR.2023.050818.


[1] Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation, 1997, 95: 522-528. 

[2] Kemp H. Left ventricular function in patients with the anginal syndrome and normal coronary angiograms [J]. American Journal of Cardiology, 1973, 32(3):375-376. 

[3] Kunadian V, Chieffo A, Camici P G, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group [J]. Eur Heart J, 2020:ehaa503. DOI:10. 1093/eurheartj/ehaa503. 

[4] Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina[J]. Int J Cardiol, 2018, 250 (1):16-20. 

[5] Mejía-Rentería H, Van Der Hoeven N, Van Dehoef T P, et al. Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests[J]. Int J Cardiovasc Imaging, 2017, 33(7):1041-1059. DOI:10. 1007/s10554-017-1136-9. 

[6] Wu Yihang, Deng Cuiyun. Research Progress of Pathogenesis and Treatment of Microvascular Angina [J]. China & Foreign Medical Treatment, 2017, 36 (14): 196-198. 

[7] Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction[J]. Circulation, 2002, 106(6):653-8. 

[8] Baumgart D, Haude M, Gorge G, et al. Augmented Alpha-Adrenergic Constriction of Atherosclerotic Human Coronary Arteries[J]. Circulation, 1999, 99(16):2090-7. 

[9] Huang Baotao, Chen Mao. Interpretation of the Newly Released European Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries:Improving the Ability of Hierarchical Diagnosis and Treatment,and Strengthening the Joint Management of General Practitioners and Specialist Physicians[J].Chinese General Practice,2021(02):125-131.

[10] Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy [J]. Mol Cell Cardiol, 2012, 52(4): 857-64. 

[11] Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO, Boomsma F, van Beusekom HM, van der Giessen WJ, VanBavel E, Duncker DJ. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ Res 2008; 102:795–803. 

[12] Grover R, Leipsic JA, Mooney J, et al. Coronary lumen volume to myocardial mass ratio in primary microvascular angina [J]. Cardiovasc Comp utTomogr, 2017, 11 (6): 423-428

[13] Hermans MP, Ahn SA, Rousseau MF. The mixed benefit of low lipoprote in (a) in type 2 diabetes [J]. Lipids Health Dis, 2017, 16 (1): 171. 

[14] GulerE, Guler GB, Kizilirmak F, et al. Evaluation of adiponectin and li-po-protein(a)levels in cardiac syndrome X[J]. Herz2015, 40:291-297

[15] HermansMP, Valensi P, Ahn SA, et al. [HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM [J]. Diabetes Metab Res Rev, 2018, 34 (1): e2950. 

[16] MishraMMuthuramu I, Kempen H, et al. Administration of apo A-I (Milano)nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hyperten- sion [J]. Sci Rep, 2020, 10(1):8382. 

[17] Zhang Yi, Zhang Yingying, Zhang Tao. Study on the diagnostic value of lipoprotein-associated phospholipase A2 combined with homocysteine for microvascular angina pectoris in middle-aged and elderly women[J]. Chinese Modern Doctor, 2022, 60 (18): 11-15. 

[18] Schroder J, Mygind ND, Frestad D, Michelsen M, Suhrs HE, Bove KB, Gustafsson I, Kastrup J, Prescott E. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. Int J Cardiol Heart Vasc 2019;24:100370. 

[19] Jakob Schroder, Naja Dam Mygind, Daria Frestad, et al. Pro-inflammatorybiomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction [J]. IJC heart and vascular, 2019, 24: 1-7. 

[20] Chen Y F, Wu K J, Wood W G. Paeonia lactiflora Extract Attenuating Cerebral Ischemia and Arterial Intimal Hyperplasia Is Mediated by Paeoniflorin via Modulation of VSMC Migration and Ras/MEK/ERK Signaling Pathway[J]. Evid Based Complement Alternat Med, 2013, 2013:482428. 

[21] Chen Bin, Wang Wei, Lv Jun, et al. The effect of inflammatory response on coronary blood flow reserve function in patients with microvascular angina [J]. Shaanxi Medical Journal, 2010, 39 (8): 990-992. 

[22] Mommersteeg PMC, Maas AHEM. Genderverschillen in psychologische klachten bijischemische hartziekte Gender differences in psychological complaints in ischemic heart diseases [J]. Ned Tijdschr Geneeskd, 2018, 162:D2961. 

[23] Jaskanwal D. Sara, MBCHB, R. Jay Widmer, et al. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobs-tructiveCoronary Artery Disease [J]. JACC Cardiovasc Interv, 2015, 8(11):1445-1453. 

[24] ThomasJ. Ford, Eric Yii, Novalia Sidik, et al. Ischemia and No Obstructive Coronary Artery Disease Prevalence and Correlates of Coronary Vaso motionDisorders. Circ Cardiovasc Interv, 2019, 12: 1-10

[25] Volterrani M, Rosano G, Coats A, et al. Estrogen acutely increases peripheral blood flow in postmenopausal women [J]. American Journal of Medicine, 1995, 99(2):119-122. 

[26] Nerla R, Tarzia P, Sestito A, et al. Effect of bariatric surgery on peripheral flow-mediated dilation and coronary microvascular function. Nutr Metab Cardiovasc Dis, 2012, 22: 626-634. 

[27] Mumma B, Flacke N. Current diagnostic and therapeutic strategies in microvascular angina. Curr Emerg Hosp Med Rep, 2015, 3: 30-37. 

[28] Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction:an update[J]. European Heart Journal, 2014, 35(17):1101. 

[29] Lanza GA, Parrinello R, Figliozzi S. Management of microvascular angina pectoris. Am J Cardiovasc Drugs, 2014, 14: 31-40. 

[30] Teresa Padro, Olivia Manfrini, Raffaele Bugiardini, et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease’. Cardiovascular Research, 2020; 116(4): 741–755. 

[31] Bairey Merz CN, Pepine CJ, Shimokawa H, et al. Treatment of coronary microvascular dysfunction [J]. Cardiovasc Res, 2020, 116(4):856-870. 

[32] Taqueti VR, di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2018, 72(21):2625-2641. 

[33] Chang Chengcheng, Wei Cong, Wu Yiling. “Minute Collaterals and Microvessels” Concept and Its Clinical Guiding Significance in Meridian and Collateral Theory [J]. Journal of Traditional Chinese Medicine, 2016, 57 (01): 7-11. 

[34] Liu Miao, Lv Xiaodong, Pang Lijian, Liao Jianbing, Wang Wenxuan. Pathogenesis of ’lung cold collaterals’ in acute stage of idiopathic pulmonary fibrosis[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2019, 34 (06): 2373-2376. 

[35] Wu Yiling. Traditional Chinese Medicine Theory of Collateral Diseases and Cardiovascular and Cerebrovascular Diseases [M], Beijing, China Science and Technology Press, 2001. 

[36] Wu Yiling. Chracters and changes of pathological mechanism in patients with collateral disease [J]. Journal of Diffcult and Complicated Cases, 2004 (05): 282-284.